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Abstract
Background: Suo Quan Wan (SQW) is a Chinese traditional prescription that has been used in clinical treatment of
lower urinary tract symptoms for centuries. However, scientific basis of SQW efficacy and mechanism is still needed.
This study investigated the effect of SQW on bladder function and transient receptor potential vanilloid 1 (TRPV1)
expression in the bladder of rats with bladder outlet obstruction (BOO). The induced changes in bladder function in
overactive bladder (OAB) rat model were observed following different periods of outlet obstruction to obtain an
appropriate rat model.
Methods: This study was carried out in two parts. In the first part, female Sprague–Dawley rats received sham
operations or partial BOO operations. Two, four, and six weeks later, the OAB model groups and control were
subjected to urodynamic tests to measure differences in bladder functions. Once the appropriate rat model was
obtained, the second part of the experiment was performed. The rat model was recreated and treated with SQW.
Urodynamic assessment was conducted, and the bladders of the rats were then removed. Immunofluorescence
staining, real-time PCR, and Western blot were performed to localize and quantify the expression of TRPV1 in the
bladder.
Results: Results of the first part indicated that at 2 and 4 weeks, the OAB model group exhibited significant
differences in urodynamic parameters, including bladder pressure, maximum voiding pressure, and maximum
bladder capacity, compared with the sham group. At 4 and 6 weeks, the OAB model group exhibited significant
differences in residual volume (RV) and non-voiding contraction frequency. Six-week OAB model group showed
much more RV but less voiding efficiency when compared with 6-week sham group or 2—and 4-week OAB model
group. Rats that underwent BOO exhibited similarities with the compensated state before four weeks and may
have entered decompensated state at six weeks. Studies conducted with 4-week OAB model were appropriate.
In part two of the experiment, unstable bladder in the OAB model group recovered bladder stability after SQW
treatment, accompanied by improved bladder hypertrophy, as well as corrected urodynamic parameters. Expression
of TRPV1 mRNA and proteins in the bladder was significantly greater in the OAB model group than that in the
control group, which subsequently decreased significantly with SQW treatment in BOO-induced rats.
Conclusions: SQW can modulate the expression of TRPV1 in accordance with the recovery of bladder function.
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Background
The Standardization Sub-committee of the International
Continence Society defines overactive bladder (OAB) as
a syndrome characterized by urgency, with or without
incontinence, usually with increased daytime frequency
and nocturia in the absence of infection or other evident
pathologies [1]. The symptoms of OAB include urge
syndrome and urgency–frequency syndrome. Various
factors and receptors in the bladder mediate these
anatomic and functional changes. Stimulation of blad-
der afferent neurons by mechanical stretch of chem-
ical irritation results in voiding responses that may be
voluntary or involuntary in nature [2]. Of these, tran-
sient receptor potential vanilloid 1 (TRPV1) has been
extensively studied.
TRPV1 is one of the most important and best
understood representatives of the TRP family [3].
TRPV1 is a non-selective cation channel that may be
activated by a wide variety of Internal and external
physical and chemical stimuli, which has been cloned
from rat dorsal root ganglia [4]. The urinary bladder
is rich with vanilliod-sensitive afferent fibers that de-
tect bladder distension or the presence of irritant che-
micals, which in turn trigger reflex bladder activity.
Clinically investigation has proved a novel approach
in treating OAB-type symptoms by modulated of
TRPV1 signaling [5]. TRPV1 is a pressure sensor in
the bladder, mediating stretch detection [6]. Moreover,
TRPV1 can also regulate urinary bladder contractions
and Sensory function [7]. It plays a crucial role in
maintaining bladder physiological function stability.
Herbals have been traditionally used for treatment
of various diseases over centuries, including lower
urinary tract symptoms (LUTS), such as OAB [8, 9].
The World Health Organization estimates that 80 %
of the world’s population uses traditional medicine for
primary health care. Women are more willingly to
take complementary and alternative medicine [10]. In
China, a wide range of Chinese medicinal herbs pre-
scription have been used to improved or cured LUTS,
such as nocturia, urgency, and child bedwetting. Suo
Quan Wan (SQW) is one of the most commonly used
traditional Chinese medicines (TCM) for treatment of
various urinary system diseases in China, the first
report of SQW was in the Southern Song Dynasty
(between 1127 and 1279 CE) [11]. SQW is a mixture
of Alpinia oxyphylla Miq., Dioscorea opposita Thunb.,
and Radix Lindera prepared in a ratio of 1:1:1, and is
used to warm kidney yang and expel cold while re-
lieving frequent urination by stopping leakage. SQW
as a representative prescription of TCM therapeutic
of nourishing the kidney and reducing urination by
increasing the expression of AQP2 mRNA, AVPR-V2
mRNA [12] and CYP11B2 mRNA, increasing the level
of Cort and ALD in blood accroding to the study of
kidney deficiency polyuria rats [13]. SQW can also
regulate the water metabolism and recovering the
physiologic function of the detrusor in polyuria model
animal [14]. Furthermore, SQW has significant effect
on clinical treatment of OAB in China, but the mech-
anism remains unclear.
An appropriate animal model is essential to studies
of pathology and mechanisms of OAB, along with
drug effects. Various species have been used as animal
models; the rat model induced via partial BOO is the
most widely used. Experimental animal studies have
demonstrated that the bladder progresses through
three sequential stages (i.e., hypertrophy, compensa-
tion, and decompensation) in partial BOO [7]. The
rat models are commonly assessed 2 [15] or 6 [16]
weeks after BOO surgery. The best time to carry out
the study is unclear.
We initially obtained an appropriate rat model by
investigating the changes in bladder function in BOO
rat models that are induced by outlet obstruction at
different time points and examined using urodynamic
tests. Appropriate rat model was used to further
study the treatment mechanism of SQW in OAB.
Considering that TRPV1 plays an important role in
the bladder, including involvement in normal voiding
function to pain sensation, this study conducted in-
vestigation about function and TRPV1 expression to
clarify acting targets and pathway of SQW to OAB,
as well as demonstrated the mechanism by which
SQW interferes with TRPV1 expression of OAB.
Methods
Ethics statement
Protocols involved were in accordance to the rules and
guidelines of the Experimental Animal Center of
Guangzhou University of Chinese Medicine and were
approved by the Guangzhou University of Chinese
Medicine Animal Care and Use Ethics Committee (NO.
00066178, 2014/02/27-2014/04/03). And the performed
of experiment was fit the international, national and
institutional animal experiment rules. The rats were
handled according to internationally accepted princi-
ples for the care and welfare of laboratory animals
(E.E.C. Council Directive 86/609, O.J. no L358, 18/12/
86). All the animal were sacrificed by anesthesia at the
end of the experiment.
Part 1 BOO rats model research
Animal grouping and surgical procedures
Fifty-four female Sprague–Dawley rats (200 ± 20 g)
were obtained from Medical Experimental Animal
Center of Guangzhou University of Chinese Medicine
for the OAB rat model experiment. The rat license
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number was SCXK (YUE) 2013–0020. The rats were
housed under a 12 h:12 h light/dark cycle at 20–24 °
C, with free access to food and water for at least one
week before the experiments were performed. Six
groups were studied and consisted of sham-operated
(2-, 4-, and 6-week groups; 8 animals per group) and
BOO-operated (OAB model) (2-, 4-, and 6-week
groups; 10 animals per group) animals.
To create the BOO model, we anesthetized female rats
via intraperitoneal administration of 3 mL/kg pentobar-
bital. The bladder and proximal urethra were exposed
via a lower abdominal midline incision. A 2–0 silk
ligature was placed around the urethra and tied in
the presence of an intra-luminally placed indwelling
polyethylene cannula with an outer diameter of
1 mm. The abdominal wall was sutured after the
polyethylene cannula was removed. Next, antibiotic
medication (penicillin-G 400,000 I.U./kg) was admin-
istered. The obstructed rats underwent urodynamic
tests at 2, 4, and 6 weeks after urethral ligature.
Urodynamic test
Urodynamic evaluation was performed using a urody-
namic measuring device (Laborite Delphis 94-R01-BT,
Canada). Rats were anesthetized via administration of
10 % urethane (4.0 mg/kg) [17]. Polyethylene tubing
with an outer diameter of 0.9 mm was inserted into
the bladder through the urethra. The tubing was con-
nected to a pressure transducer and a Harvard syringe
pump using a three-way stopcock to record intra-
vesical pressure and infuse saline into the bladder.
After the bladder was emptied, cystometrography was
performed via saline infusion at 0.2 mL/min. Max-
imum voiding pressure (MVP) and bladder pressure
(BP) were then measured. Pumping was stopped as
soon as urine was observed at the external orifice of
the urethra. Bladder pressure obtained at this time
was BLPP. Residual volume (RV) was measured by
withdrawing intra-vesical fluid through the catheter.
Maximum bladder capacity (MBC) was calculated as
infusion speed multiplied by time. Voided efficiency
(VE) was calculated as (MBC − RV)/MBC * 100 %.
Bladder compliance (BC) was calculated as MBC/
BLPP * 100. The number of non-voiding contractions
(NVC) was measured during the filling period [18].
The values for the individual rats represent the means
of two or three voiding cycles.
Part 2 Effects of SQW on TRPV1 experession study
Drug preparation
In our study, the SQW was purchased from Hunan
Hansen Pharmaceutical Co. Ltd. Briefly, the process and
production are as follows, all these three components
are weighed in the ratio of 1:1:1 and well-mixed after
grinded into powder. Using appropriate distilled water
to help these powder make into pills. According to
the Chinese Pharmacopeia [19], assurance of quality
control for SQW is validated and linderane is the
recorded reference standard of SQW. HPLC and TLC
were used to test these typical chemicals of SQW in
our present experiment [20] (Data submitted as
Additional file 1 and 2).
Animal grouping and surgical procedures
After the appropriate rat model was selected, 84 were
used to study the effects of SQW on TRPV1 expres-
sion under similar conditions. Five groups, namely,
sham-operated group, OAB model group, SQW-
treated low group (treated with SQW at 293 mg/kg/
day), SQW-treated middle group (treated with SQW
at 585 mg/kg/day), and SQW-treated high group
(treated with SQW at 1170 mg/kg/day), were investi-
gated. All animals were subjected to intra-gastric
administration.
All animals received the same BOO-operated or sham-
operated procedure. Drug administration was performed
after 2 days and continued for 4 weeks.
Urodynamic test
Urodynamic evaluation was performed following the
former procedures. NVC was measured during the
filling period and micturition times, and voided vol-
ume was recorded within 1 h after the last urody-
namic test.
Bladder harvesting and processing
All rats were sacrificed, and their bladders were
excised at the bladder outlet and weighed [21]. The
bladder was cut vertically and divided into three
parts (one quarter for RT-PCR, two quarters for
Western blot, and the rest for immunofluorescence
staining). The portion used for RT-PCR and Western
blot was stored in liquid nitrogen until needed. The
portion used for immunofluorescence staining was
embedded in optimum cutting temperature com-
pound (Sakura, Japan) tissue freezing medium, quick-
frozen in liquid nitrogen, and then stored at −80 °C until
needed.
Immunofluorescence staining
For immunofluorescence staining, the frozen tissue was
sectioned at 12 μm. Bladder tissue slides were processed
for routine immunohistochemistry. Frozen sections were
fixed in cold acetone for 10 min. Slides were washed
three times in PBS for 5 min and then blocked with 5 %
BSA for 60 min. After incubation in blocking solution,
the slides were incubated overnight at 4 °C with rabbit
anti-TRPV1 and washed three times in PBS for 5 min.
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The tissues were then incubated with goat anti-rabbit
IgG at 37 °C for 90 min and washed three times in PBS
for 5 min. Tissues were mounted on slides and exam-
ined under laser scanning confocal fluorescence micro-
scope (LSM 710; Carl Zeiss, Germany), at 488 nm.
Real-time PCR
Total RNA from the bladder tissue was isolated by TRIZOL
reagent and reverse transcribed into cDNA using RT-PCR
kits (Thermo Fisher Scientific, USA) according to the man-
ufacturer’s instructions [22]. The synthesized cDNA was
amplified by quantitative RT-PCR on an ABI Prism 7500
system using SYBR Green RT-PCR master mix reagent
(Thermo). Table 1 shows the expected RT-PCR product
sizes and primers used in this study. The amplification cycle
was 95 °C for 15 min, 40 cycles of 95 °C for 15 s, 60 °C for
30 s, and 72 °C for 30 s. Data were collected and analyzed
by complementary computer software. Relative gene
expression was calculated using the 2−ΔΔCt method and
normalized to GAPDH expression in each sample [23].
Western blot
The tissue was homogenized, and total proteins were
extracted using a total protein extraction reagent kit
[24]. The protein concentration was measured by using
a BCA protein assay kit (Pierce, USA). Protein samples
were separated on SDS-PAGE gels at 70–90 V and
transferred to PVDF membranes by using a transblot-
ting apparatus (Bio-Rad Laboratories, USA) for 70 min
at 90 V. The membranes were blocked with 5 % (w/v)
non-fat milk at room temperature for 90 min and
subsequently incubated overnight at 4 °C with rabbit
anti-TRPV1 (1:1000; Abcam). The immune-labeled
membranes were washed once with PBST for 15 min,
followed by two separate washes (5 min/wash). The
membranes were then probed with secondary antibody
(1:2000; Millipore) at room temperature for 60 min in
5 % non-fat milk. The membrane was washed three
times with PBST, and protein bands were visualized
with ECL Western blotting detection reagents (Bio-Rad
Laboratories, USA). The intensity of each target protein
band was analyzed using an Image Station 4000R
(KODAK, USA) and expressed relative to β-actin
density.
Data analyses
Data are expressed as means ± standard errors of mean. For
multiple comparisons, repeated-measure ANOVA (Holm-
Sidak) was used. Pairwise and non-pairwise comparisons
were performed using Student’s t-test. Linear regression
analyses were also utilized where appropriate, and
ANCOVA was used to compare regression slopes and in-
tercepts. The percentage of VE among groups was mea-
sured using Pearson chi-square test and presented as mean
difference. These calculations were performed using SPSS
13.0 and were based on the number of individuals. P < 0.05
was considered statistically significant.
Results
Part 1 BOO rats model research
Pressures, volumes, and NVC frequencies are provided in
Table 2. The 2- and 4-week OAB model groups exhibited
significant increases in BP and MVP, as well as bladder
capacity, compared with the corresponding sham groups.
With regard to NVC, only 42 % (5 of 12 rats) of the
2-week OAB model group exhibited statistical differences
compared with the sham group. However, in the 4-week
OAB model group, 89 % (8 of 9 rats) exhibited significant
increase in DO, as well as RV, compared with the sham
group. After 6 weeks, the OAB model group exhibited an
increase in RV and NVC, whereas voiding efficiency de-
creased significantly when compared with the 6-week
sham group.
Previous studies also compared urodynamic values
among 2-, 4-, and 6-week OAB model groups. Pressures
and volumes were similar between 2- and 4-week OAB
model groups, but RV and NVC of the 4-week group
were higher. Compared with 2- and 4-week OAB model
group, RV of the 6-week OAB model group increased,
whereas voiding efficiency decreased (Fig. 1a and b).
Bladder pressures showed a slight decrease, but not sta-
tistically different. Moreover, the highest NVC frequency
was observed in the 4-week group.
Part 2 Effects of SQW on TRPV1 expression
Based on the above mentioned studies, the 4-week
OAB rat model was used to carry out the part 2 ex-
periments. In accordance with previous experiment,
the urodynamic results of OAB model groups showed
significant increase in bladder pressures and capacity,
NVC, and micturition frequency compared with sham
group. SQW treatment with different dosages was
beneficial to the OAB rat model, which exhibited sig-
nificant decrease in bladder pressures and reduced
MBC, RV, Vv, NVC, and micturition frequency dose
dependently (Fig. 2).
After urodynamic tests were conducted, bladder
weight was measured, and the ratio of bladder weight to
body weight was calculated. The ratio of bladder weight
Table 1 Primers used for quantitative real-time polymerase
chain reaction analysis of GAPDH and TRPV1
cDNA/product sizes Sequence(5′-3′)
GAPDH Forward primers: ggtgaaggtcggtgtgaacg
Reverse primers: ctcgctcctggaagatggtg
TRPV1 Forward primers: gtttacctcgtccaccctga
Reverse primers: agagagccatcaccatcctg
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to body weight of OAB model rats was significantly in-
creased (Fig. 3). Drug administration significantly re-
duced these indices and showed dose dependence in
SQW treatment (Fig. 4).
With regard to TRPV1 expression, immunofluores-
cence staining using scanning laser confocal analysis of
bladder revealed that TRPV1 was localized in the
bladder (Fig. 5). Densitometric analysis relative to
TRPV1 showed that SQW could reduce TRPV1 expres-
sion in OAB rat bladder. RT-PCR and Western blot
analysis demonstrated that OAB model increased the
expression of TRPV1 mRNA and proteins in the
bladder compared with the sham group (P < 0.01).
Moreover, SQW treatment significantly reduced the ex-
pression of TRPV1 mRNA (Fig. 6) and proteins in the
presence of OAB model (Fig. 7).
Discussion
To the urinary bladder, the physiological function is
store and periodic urination, and this function is
regulated by the contraction and relaxation of the
bladder wall which comprises by the detrusor smooth
muscle [25]. As demonstrated in animal partial BOO
experimental studies, the bladder undergoes three
sequential stages, namely, hypertrophy, compensation,
and decompensation [26].
Partial BOO induced rabbit OAB model results in
increased bladder mass which induced by immediate
increase in micturition pressure, smooth muscle
hypertrophy, collagen synthesis and deposition, and
urothelial and interstitial fibroblast proliferation [27, 28].
Previous studies showed that at 2 and 4 weeks after
BOO, rats exhibit increased bladder pressure, and that
during these periods, the animals require more pres-
sure to empty the bladder, which leads to greater en-
ergy loss and results in increased RV. However, with
regard to NVC frequency, the 2-week BOO group
was not different from the sham group, indicating
that during this period, the bladder enlarged to retain
more urine and exhibited increased pressure to empty
the bladder, but these processes did not lead to de-
trusor dysfunction [29]. This observation is similar to
that of hypertrophy stage.
Right after that, the bladder progress in compensated
stage; resistance to urine flow generation either remain
stable or increases to greater than the control, and the
empty ability of bladder decreases [30]. In the present
study, most of the urodynamic parameters, including
Table 2 Urodynamic variables at 2, 4, and 6 weeks after BOO
N Bladder pressure
(p/mmH2O)
Max. voiding pressure
(p/mmH2O)
Residual volume
(V/ml)
Max. Bladder
capacity (V/ml)
Voided
efficiency %
Bladder compliance
(ml/mmH2O)
Non-voiding
contractions
2w sham 8 48.0 ± 2.2 49.7 ± 2.4 0.22 ± 0.02 0.90 ± 0.09 80 1.79 ± 0.22 0.08 ± 0.05
2WBOO 8 60.5 ± 2.0## 62.3 ± 2.2## 0.35 ± 0.09 1.68 ± 0.18# 76 2.27 ± 0.30 1.08 ± 0.49
4w sham 8 49.1 ± 1.5 50.4 ± 1.4 0.22 ± 0.03 1.04 ± 0.16 79 1.89 ± 0.33 1.06 ± 0.38
4WBOO 8 61.0 ± 3.0## 64.18 ± 3.0## 0.39 ± 0.06# 1.72 ± 0.22# 77 2.63 ± 0.44 6.60 ± 2.00#
6w sham 8 54.2 ± 0.6 55.3 ± 0.5 0.50 ± 0.09 1.78 ± 0.07 72 2.24 ± 0.12 1.62 ± 0.70
6WBOO 8 57.0 ± 2.1 58.2 ± 2.5 0.81 ± 0.17# 1.84 ± 0.26 55# 3.00 ± 0.47 3.85 ± 0.65#
Paired t-test: #P < 0.05; ##P < 0.01. Student’s t-tests or Mann–Whitney U-tests when data were not normally distributed for comparisons between the BOO and sham
groups at the same time points
Fig. 1 Comparisons of the residual volumes (RV) and vioding efficency
(VE) comparisons of the OAB group at 2, 4 and 6 weeks. A: RV of 2, 4
and 6 weeks OAB group; B: VE of 2, 4 and weeks OAB group. Values are
expressed as mean ± SEM. ★★= P < 0.01, ★= P < 0.05 vs 2 and 4 weeks
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BP (which is related to the pressure at the beginning of
micturition), MVP (which is related to the maximum
bladder pressure during the micturition cycle), bladder
capacity, and BC, of the 4-week BOO animals were
similar to the 2-week animals. At 4 weeks, the OAB
model significantly increased the RV and NVC com-
pared with both the 4-week sham and 2-week OAB
model groups. This finding indicates that the detrusor
destabilized, which is similar to the shift from the com-
pensated stage to the decompensated stage [31].
Without treatment, the compensated stage could be
lasts for quite a long time then enters the final phase.
During the decompensated stage, bladder function
destabilize led to progressive decrease in both phasic
contraction and tonic contraction response to stimula-
tion, as well as progressive loss of the empty ability of
bladder, an increase in RV as consequence [26]. Similar
phenomena have been shown in previous studies.
After 6 weeks of progression, the decrease in contrac-
tion exhibited by BOO animals may be due to energy
deprivation [32]. RV significantly increased further,
when compared to the 2- and 4-week OAB model an-
imals, because of progressive energy loss. The above
characteristics are similar to those of the decompen-
sated stage. Detrusor overactivity subsequently occurs
during intravesical instillation, and the transition from
compensation to decompensation which is character-
ized by decreased detrusor contraction frequency in
the non-voiding phase [26].
The BC values of the OAB model groups were not
significantly different from those of the sham group
during any of the three periods. However, lower values
Fig. 3 Micturition frequency of sham group, OAB model group, SQW
treated groups (treated with SQW at 293, 585, 1170 mg/kg/day)
were recorded within 1 h after the last urodynamic tests. Values
are expressed as mean ± SEM. ★★= P < 0.01 for comparisons between
the OAB model group vs sham group. ## = P < 0.01 vs for comparisons
between the SQW treated group OAB model group
Fig. 2 Urodynamic parameters of sham group, OAB model group, SQW treated groups (treated with SQW at 293, 585, 1170 mg/kg/day) are
exhibited in the current figures, including bladder pressure (BP), maximum voiding pressure (MVP), maximum bladder capacity (MBC), residual
volume (RV), non-voiding contraction (NVC). Values are expressed as mean ± SEM. ★ = P < 0.05, ★★ = P < 0.01 for comparisons between the OAB
model group vs sham group. # = P < 0.05, ## = P < 0.01 for comparisons between the SQW treated group OAB model group
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were observed in the sham groups [29]. Considering
that the present study was designed with corresponding 2-
, 4-, and 6-week sham groups, which were different from
most previous studies, we made a comparison among the
three sham groups. However, with the progression to six
weeks, the sham-operated rats exhibited changes in pres-
sure and volume but were not statistically different,
suggesting that subsequent studies should include a corre-
sponding sham group.
The present study revealed urodynamic changes that
occur in rats in three different stages that follow partial
BOO. Comparison of urodynamic results indicate that
rats with BOO at four weeks were similar to the com-
pensated stage and may enter the decompensated stage
six weeks after BOO. The sham-surgery may negatively
and progressively affect bladder function, which requires
further research. Above all, rat model for OAB study
was chosen before the decompensated stage, four weeks
prior in our study.
Anticholinergics, specifically anti-muscarinic agents,
are the most common medications prescribed for OAB.
However, herbal treatments are an increasingly popular
alternative for treating OAB [33]. The TRPV1 agonist
Fig. 5 Inmunofluorescence staining used Laser Confocal Scan Analysis of TRPV1 in Bladder. a: OAB model group. b:sham group, c: SQW treated
high group (treated with SQW at 1170 mg/kg/day), d: SQW treated middle group (treated with SQW at 585 mg/kg/day) and e: SQW treated low
group (treated with SQW at 293 mg/kg/day). The last figure is densitomric analysis relative to TRPV1 of each group. Values are expressed as
mean ± SEM. # = P < 0.05, ## = P < 0.01 vs OAB model group
Fig. 4 The ratio of bladder weight to body weight of sham group,
OAB model group, tolterlodine treated group, capsazepine group
(intravesical instillation at 10uM for 30 min before cystometrography),
SQW treated group (treated with SQW at 293, 585, 1170 mg/kg/day).
Values are expressed as mean ± SEM. ★★= P < 0.01 for comparisons
between the OAB model group vs sham group. ## = P < 0.01 for
comparisons between the SQW treated group OAB model group
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capsaicin is also derived from herbal chili peppers;
this agonist can bind with TRPV1 receptor, leading to
reduction in neurotransmitter [34]. Results of previ-
ous studies exhibited that BOO rats have high expres-
sion of TRPV1 mRNA and proteins in the bladder.
BOO rats exhibited increased bladder weight. More-
over, results showed increases in bladder pressures,
capacity, non-voiding bladder contractions, and mic-
turition frequency. These findings confirm the signifi-
cant role of TRPV1 in bladder function, which is
related to OAB.
The use of medicinal herbs has increased as part of
complementary and alternative medicine [35]. Trad-
itional prescription SQW has been used on clinical treat-
ment of LUTS for decades and has shown to improve
bladder function, as well as quality of life of OAB pa-
tients. Many potential targets exist in the treatment of
LUTS because its pathophysiology is multifactorial [36].
SQW is composed of A. oxyphylla Miq, Dioscorea rhizome
Thunb., and Aconitii tuber [the last two being ingredients
in another Chinese herbal compound prescription
Ba-Wei-Di-Huang-Wan (Hachi-mi-jio-gan)], which are
speculated to possess a relaxant effect on the acetylcholine-
induced contraction of smooth muscle and are used clinic-
ally for the treatment of LUTS [8]. In our study, OAB
model rats treated with SQW exhibited decreased TRPV1
expression in the bladder, as well as reduced non-voiding
bladder contractions and micturition frequency, indicating
that SQW may have stabilizing effect on the excitabil-
ity of bladder smooth muscle during filling related
with neurogenic pathway via regulated TRPV1 expres-
sion. SQW also decreased bladder weight of OAB
model rats; it also decreased bladder pressure, but
improved micturition efficiency, which results in de-
creased RV. These results demonstrate that SQW can
slow down the progress of OAB and improve overall
bladder function, even the physical condition of
animals.
Previous studies indicated that SQW treatment on
OAB is related with TRPV1 regulation. Urothelium
pathway may be involved in the mechanisms of SQW
work through TRPV1 channel to adjust bladder function.
Therefore, we aim to research on these mechanisms
further.
Conclusions
The main findings of the present study are as follows.
First, the expression of TRPV1 increased in the blad-
der after induction of BOO, which decreased later in
the SQW-treated group, compared with the OAB
model group, and showed dose-dependent effects.
Second, results of TRPV1 expression in the bladder
are in agreement with urodynamic change, according
to the induction of OAB model and SQW treatment.
Furthermore, the outcome of the current study pro-
vides strong foundation to our hypothesis that treat-
ment of SQW on OAB is related to TRPV1 and
fulfills the scientific basis of the efficacy and mecha-
nisms of SQW.
-Actin (42kDa)
TRPV1 (92 kDa)
Fig. 7 The effect of SQW treated on TRPV1 protein expression in
bladder. A: sham group, B: OAB model group, C: SQW treated high
group (treated with SQW at 1170 mg/kg/day), D: SQW treated
middle group (treated with SQW at 585 mg/kg/day) and E: SQW
treated low group (treated with SQW at 293 mg/kg/day). Values are
expressed as mean ± SEM.# = P < 0.05, ## = P < 0.01 vs OAB
model group
Fig. 6 The effect of sham group, OAB model group, SQW treated
group (treated with SQW at 293, 585, 1170 mg/kg/day) on TRPV1
mRNA expression in bladder. Values are expressed as mean ± SEM.
★ = P < 0.05, ## = P < 0.01 vs OAB model group
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